Russian manufacturers strengthen their positions in the domestic veterinary pharmaceuticals market

The Russian retail market for veterinary pharmaceuticals continues to grow, while its structure is undergoing notable changes. Online channels are increasing pressure on traditional retail, domestic manufacturers are demonstrating accelerated growth, and foreign companies are losing volumes. These findings are presented in an analytical report by RNC Pharma, unveiled as part of the business program of the Pharmtech & Ingredients 2025 exhibition.

As of January–September 2025, the retail market volume for veterinary pharmaceuticals reached USD 482.30 million at retail prices including VAT, while long-term sales growth amounted to +16.1% in value terms. The primary growth driver was the online channel: its share increased to 28.6%, compared to no more than 8.9% in 2022. The shift in demand toward marketplaces is leading to stagnation in traditional veterinary retail, particularly in Moscow and Saint Petersburg.

The sales structure by country of origin is also changing. Russian manufacturers increased turnover by 37%, while German companies lost around 30% of sales over the same period. As a result, the share of domestically produced products rose to 54.9% of the total market, while the imported product share declined to 45.1%.

Inflation in the segment remains high: the price index compared with the first three quarters of 2024 stands at 13.3%. At the same time, prices for Russian-made products are increasing faster than those for imported veterinary pharmaceuticals. The average online purchase value is significantly higher than offline: USD 16.03 versus USD 8.77, respectively.

The market assortment includes 1,883 brands, which is 28 fewer than a year earlier. The number of SKUs increased by 167 items, while the number of international nonproprietary names declined, mainly due to vaccines for livestock.

Source: t.me/rncpharma